All In Biotech

Drug Trial Radar · NCT06482177

The COAT Trial: Cequa's Onset of Action Trial

The COAT Trial: Cequa's Onset of Action Trial: an Investigation of CEQUA's Speed of Onset in Improving Ocular Surface Health in Dry Eye Patients

Last checked: Nov 20, 2026Latest source record: Jul 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Oct 12, 2023

Primary completion

Jun 5, 2024

Study completion Jun 5, 2024

Sponsor

Lead sponsor
Research Insight LLCIndustry
Sponsor type
Industry
First posted
Jul 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Cequa's Onset of Action Trial: an Investigation of CEQUA's Speed of Onset in Improving Ocular Surface Health in Dry Eye Patients

Conditions

  • Dry Eye

Interventions

  • Cyclosporine ophthalmic solutionDrug

    Cyclosporine BID in the study eye

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in corneal high order aberrations (HOA)Time frame: After 7, 14, and 28 days of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Harvard Eye Associates

    Laguna Hills, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.